The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Monoclonal antibodies, first introduced in cancer therapy and to prevent allograft rejection, represent new pharmacological tools for the treatment of autoimmune diseases. With the knowledge of immunological movements in autoimmunity, it is now possible to target each single step of the immune process, from the activation of T lymphocytes in lymph nodes to the formation of the immunological synapse, and to T cell differentiation and cytokine production. However, this approach is still not devoid of adverse effects. In fact, even if monoclonal antibodies exert selective immunomodulation by targeting only cells expressing a specific antigen, a widespread perturbation of the immune system is induced, leading to a predisposition for infections and infestations and to the occurrence of tumours.

Original languageEnglish
JournalNeurological Sciences
Volume31
Issue numberSUPPL. 3
DOIs
Publication statusPublished - 2011

Fingerprint

Autoimmune Diseases
Chronic Disease
Immunological Synapses
Monoclonal Antibodies
T-Lymphocytes
Immunomodulation
Autoimmunity
Allografts
Cell Differentiation
Immune System
Neoplasms
Lymph Nodes
Pharmacology
Cytokines
Antigens
Therapeutics
Infection

Keywords

  • Biological drugs monoclonal antibodies autoimmune diseases multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology
  • Medicine(all)

Cite this

@article{14d0d89abca74620babc65221dd74588,
title = "The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases",
abstract = "Monoclonal antibodies, first introduced in cancer therapy and to prevent allograft rejection, represent new pharmacological tools for the treatment of autoimmune diseases. With the knowledge of immunological movements in autoimmunity, it is now possible to target each single step of the immune process, from the activation of T lymphocytes in lymph nodes to the formation of the immunological synapse, and to T cell differentiation and cytokine production. However, this approach is still not devoid of adverse effects. In fact, even if monoclonal antibodies exert selective immunomodulation by targeting only cells expressing a specific antigen, a widespread perturbation of the immune system is induced, leading to a predisposition for infections and infestations and to the occurrence of tumours.",
keywords = "Biological drugs monoclonal antibodies autoimmune diseases multiple sclerosis",
author = "Valeria Bruno and Giuseppe Battaglia and Ferdinando Nicoletti",
year = "2011",
doi = "10.1007/s10072-010-0382-6",
language = "English",
volume = "31",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases

AU - Bruno, Valeria

AU - Battaglia, Giuseppe

AU - Nicoletti, Ferdinando

PY - 2011

Y1 - 2011

N2 - Monoclonal antibodies, first introduced in cancer therapy and to prevent allograft rejection, represent new pharmacological tools for the treatment of autoimmune diseases. With the knowledge of immunological movements in autoimmunity, it is now possible to target each single step of the immune process, from the activation of T lymphocytes in lymph nodes to the formation of the immunological synapse, and to T cell differentiation and cytokine production. However, this approach is still not devoid of adverse effects. In fact, even if monoclonal antibodies exert selective immunomodulation by targeting only cells expressing a specific antigen, a widespread perturbation of the immune system is induced, leading to a predisposition for infections and infestations and to the occurrence of tumours.

AB - Monoclonal antibodies, first introduced in cancer therapy and to prevent allograft rejection, represent new pharmacological tools for the treatment of autoimmune diseases. With the knowledge of immunological movements in autoimmunity, it is now possible to target each single step of the immune process, from the activation of T lymphocytes in lymph nodes to the formation of the immunological synapse, and to T cell differentiation and cytokine production. However, this approach is still not devoid of adverse effects. In fact, even if monoclonal antibodies exert selective immunomodulation by targeting only cells expressing a specific antigen, a widespread perturbation of the immune system is induced, leading to a predisposition for infections and infestations and to the occurrence of tumours.

KW - Biological drugs monoclonal antibodies autoimmune diseases multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84856384340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856384340&partnerID=8YFLogxK

U2 - 10.1007/s10072-010-0382-6

DO - 10.1007/s10072-010-0382-6

M3 - Article

VL - 31

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 3

ER -